FemtoTechnologies Secures $17 Million in Private Placement to Advance Feminine Wellness Technology

FemtoTechnologies Inc. (Nasdaq:BCAN), a FemTech company specializing in feminine wellness products, has entered into definitive agreements with institutional investors for a private placement raising approximately $17 million. The offering involves the sale of Common Units and Pre-Funded Units at $4.17 per unit, consisting of common shares or pre-funded warrants along with Series A and Series B warrants exercisable for additional common shares.

The Series A Common Warrants carry an initial exercise price of $5.21 per share and remain exercisable for 60 months, while the Series B Common Warrants have an initial exercise price of $12.51 per share with a 30-month expiration period. The transaction, expected to close on February 27, 2025, will provide the company with significant capital for general corporate purposes and working capital requirements. Aegis Capital Corp. served as the exclusive placement agent for the private placement.

This funding round represents a critical milestone for FemtoTechnologies as it seeks to advance its proprietary Smart Release System technology, which incorporates machine learning and artificial intelligence to enhance feminine wellness. The company's flagship product, Sensera, recently received recognition as a CES Innovation Awards® 2025 honoree in the AI category, highlighting the innovative nature of its technology platform.

The securities were offered only to accredited investors in a private placement transaction not involving a public offering and have not been registered under the Securities Act of 1933. The company has agreed to file registration statements with the SEC covering the resale of the common shares and shares issuable upon warrant exercise, providing investors with potential liquidity options. For additional information about the company's technology and products, visit https://www.femtocorp.com.

The successful completion of this $17 million financing demonstrates strong institutional investor confidence in FemtoTechnologies' business model and technology platform. The capital infusion will enable the company to accelerate research and development activities, scale manufacturing capabilities, and expand market reach for its feminine wellness solutions. This funding comes at a pivotal time as the FemTech sector continues to experience rapid growth and increased attention from both consumers and investors seeking innovative solutions in women's health and wellness.